TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04040036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children watch applications by wearing the virtual headset during the blood draw.
Description: wearing the virtual headset

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children watch applications by wearing the virtual headset during the blood draw.
Description: wearing the virtual headset
Study: NCT04982861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime Trihydrate 100 mg/5 mL Dry Syrup
Description: Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprax 100 MG in 5 mL Oral Suspension
Description: Participants received a single dose of 5 mL of Suprax with 240 mL of water
Study: NCT03166722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: SpO2 and HR monitoring and routine treatment during immediate transition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
Study: NCT00570063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-02545920
Description: Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
Study: NCT04857528

Intervention type: RADIATION
Intervention: Radiation Treatment With or Without Chemotherapy
Description: Standard care radiation treatment.

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV Genotyping (HPV DNA Test)
Description: A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing Archival Tumor Tissue
Description: Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.

Intervention type: OTHER
Intervention: Physical Exam
Description: A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)
Description: Tests that use computers and/or rotating x-rays to scan/create images of the body.
Study: NCT03036657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC acupuncture needles
Description: Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
Description: Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrostimulator 6c.Pro, Pantheon Research, Venice, CA
Description: Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min
Study: NCT03207776

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
Study: NCT01684202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
Study: NCT03207776

Intervention type: OTHER
Group type: OTHER
Intervention: COPD Clinical Pathway
Description: A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
Study: NCT00025025

Intervention type: OTHER
Intervention: sample testing

Intervention type: OTHER
Intervention: sample testing
Study: NCT01159730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VB-201 or Placebo
Study: NCT02058069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Arm Assisted Total Knee Arthroplasty
Description: The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
Study: NCT01573585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAST protocol
Description: The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
Study: NCT00293787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
Description: Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5%
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT01668745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Early measles vaccine
Study: NCT00987532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-focused intervention
Description: The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: twice weekly gym lessons
Description: twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: twice weekly gym lessons
Description: twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
Study: NCT04507464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
Study: NCT02548832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus Bezafibrate
Description: Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner.
Study: NCT00191308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Non-Small Cell Lung Cancer (NSCLC) surgery
Description: All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
Study: NCT01433172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase I - GM.CD40L.CCL21 Vaccinations
Description: This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase II - GM.CD40L cells Vaccinations
Description: Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase II - GM.CD40L.CCL21 Vaccinations
Description: This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
Study: NCT01361893

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Counseling
Description: We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
Study: NCT02598206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Description: Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets.
Study: NCT00728273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: worm treatment and multiple micronutrient fortified biscuits
Description: A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: worm treatment and multiple micronutrient fortified biscuits
Description: A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.
Study: NCT04548336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery group will have to imagine motor gestures of static and dynamic balance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Action observation group will have to observe static and dynamic equilibrium motor gestures

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group will watch a video of nature without a human component.
Study: NCT00357734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
Study: NCT02305069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Described elsewhere

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Amino Acids
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Amino Acids
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [2H5]phenylalanine
Description: Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [2H5]phenylalanine
Description: Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [1-13C]leucine
Description: Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [1-13C]leucine
Description: Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
Study: NCT00996073

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Interbody Fusion with Autograft
Description: Single Dose Autograft Surgical Implantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar Interbody Fusion with NeoFuse
Description: Single Dose NeoFuse Surgical Implantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar Interbody Fusion with NeoFuse
Description: Single Dose NeoFuse Surgical Implantation
Study: NCT02478606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Stretching Exercises
Description: The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Stretching Exercises
Description: The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
Study: NCT01172860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVe endoscopic electroporation
Description: The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
Study: NCT03334201

Intervention type: OTHER
Group type: OTHER
Intervention: Western Diet
Description: high fat (40%), high sugar (25%) and low fiber (15g/day)

Intervention type: OTHER
Group type: OTHER
Intervention: Western Diet
Description: high fat (40%), high sugar (25%) and low fiber (15g/day)

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Western Diet
Description: low fat (25%), low sugar (15%), high fiber (30g/day)

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Western Diet
Description: low fat (25%), low sugar (15%), high fiber (30g/day)
Study: NCT01476527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
Study: NCT02923557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Description: single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
Study: NCT00386191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990C)
Description: oral administration
Study: NCT01970306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatriStem PSM
Description: All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
Study: NCT02348996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: status of overhydration determine by BCM once a week to determine dry weight

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluation
Description: Doctors or nurses will evaluate patients on a daily basis and determine dry weight
Study: NCT01470456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR3419
Description: Pharmaceutical form:solution for infusion Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT02782286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The patients randomised to this arm will receive 30 mg intravenous ketorolac.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
Study: NCT02773485

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Radiation
Description: The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy
Description: This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.